Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability and Bioequivalence of Niraparib and Abiraterone Acetate Formulations in Prostate Cancer
NCT04577833Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 1, randomised, open-label trial of niraparib and Abiraterone Acetate Tablets (I) in metastatic castration-resistant prostate cancer (mCRPC) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Analyte Concentration at Steady State, Area Under the Plasma Concentration-time Curve from Time Zero to 24 Hours at Steady State and 2 more. Started Nov 2020; status: active, not recruiting.
02
Drugs
niraparibAbiraterone Acetate Tablets (I)
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04577833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04577833.